Clinical Trials Logo
NCT number NCT01219348
Study type Interventional
Source Herlev Hospital
Contact
Status Completed
Phase Phase 1
Start date June 2010
Completion date August 2012

Clinical Trial Summary

Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial.

Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.


Clinical Trial Description

Background: Non small-cell lung cancer (NSCLC) is a common disease with a poor prognosis when locally advanced or metastasized, despite advances in surgery, chemo- and radiation therapy.

In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.

IDO has recently been recognized as an important factor in immune regulation and development of immune tolerance in the microenvironment of cancer cells. Cells that represent IDO at their surface are known to inhibit the immune system. IDO expression is seen both in cancer cells and antigen presenting cells. The vaccination against IDO expressing cells is therefore two-sided. The vaccination therapy is thought to block the development of immune tolerance induced by IDO expressing cells. At the same time the investigators aim to stimulate the production of IDO specific T-cells, hence facilitating the elimination of IDO positive tumour cells. The primary end points are safety and toxicity evaluation. Secondary end points are immunological and clinical response.


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
 Recruiting NCT02939729 - Physiotherapy Prehabilitation in Patients Undergoing Cardiac or Thoracic Surgery N/A
 Recruiting NCT02869789 - A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Phase 3
 Not yet recruiting NCT02795923 - Nivolumab Alone or in Combination With Decitabine/Tetrahydrouridine in Non-small Cell Lung Cancer Phase 2
 Not yet recruiting NCT02872701 - OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules Phase 2
 Recruiting NCT02474355 - Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Phase 3
 Recruiting NCT02538666 - A Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Phase 3
 Recruiting NCT02444741 - MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
 Recruiting NCT02558101 - Lung Screen Uptake Trial N/A
 Recruiting NCT02513563 - AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Phase 2
 Recruiting NCT02565017 - Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System N/A
 Recruiting NCT02507778 - Circulating Tumor Cells Spillage After Pulmonary Biopsy N/A
 Recruiting NCT02308709 - Novel Lung Functional Imaging for Personalized Radiotherapy Phase 1
 Recruiting NCT02196844 - Yoga Program for Lung Cancer Patients and Caregivers N/A
 Recruiting NCT02115464 - Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy Phase 2
 Completed NCT02106143 - RejuvenAirâ„¢ System Lobectomy Safety and Histology Study Phase 1
 Completed NCT02233842 - Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors N/A
 Recruiting NCT01972386 - EBUS/Spectrum Analysis N/A
 Recruiting NCT01852838 - The Contribution of Induced Glycolysis to the Exhaled Volatile Organic Compounds' (VOCs) Signature in Lung Cancer N/A
 Recruiting NCT02017509 - Immunoscore in Rectal Cancer N/A